Published: May 26, 2016

Introduction {#sec1}
============

Induced pluripotent stem cells (iPSCs) can be generated from somatic cells by introducing *Oct4*, *Sox2*, *Klf4*, and *c-Myc* ([@bib35]). This can be achieved by reprogramming the transcription network and epigenetic signature of the parental somatic cells. iPSCs have several benefits for basic research, drug innovation, and regeneration therapy. However, recent studies have reported genetic and epigenetic variations with iPSCs ([@bib15], [@bib19], [@bib28], [@bib29], [@bib32], [@bib34]), which influences gene expression and could lead to functional diversity within iPSC replicates ([@bib20]). In fact, several studies have reported the heterogeneous differentiation potential among generated iPSC clones compared with those of embryonic stem cells (ESCs) ([@bib6], [@bib14], [@bib25]). It is important that every iPSC clone shows high quality without variation for basic research and clinical purposes. Many attempts have been made to solve these problems by various methods ([@bib8]), but not all iPSCs exhibit quality as high as that of ESCs.

The reprogramming of somatic cells was originally demonstrated by producing cloned frogs using somatic cell nuclear transfer (SCNT) into *Xenopus* oocytes ([@bib11]). Reprogramming of mammalian somatic cells has also been achieved using SCNT into oocytes, including those of mice and humans ([@bib26], [@bib41]). The procedure of SCNT into oocytes is similar to iPSC generation with respect to the time course of extinction of the parental gene-expression profile and activation of pluripotency ([@bib5]). Both somatic cell reprogramming processes involve dynamic rearrangement of the epigenetic profile ([@bib1], [@bib16]). These findings suggest that the constituents of oocytes include a reprogramming-promoting factor. The linker histone H1 family binds to linker DNA and generates higher-order chromatin structures to control gene expression. Most members of the linker histone family consist of somatic linker histones that condense chromatin; therefore, these structures generally repress global gene-transcription activity ([@bib13], [@bib33]). Mammalian oocytes contain the maternal-specific linker histone *H1foo*, a homolog of the *Xenopus* linker histone *B4*. *H1foo* is specifically expressed during the germinal vesicle stage and until the late two-cell or early four-cell stage, coincident with the early wave of zygotic genome reactivation ([@bib9], [@bib38], [@bib39]). In *Xenopus* SCNT, somatic linker histones in transplanted nuclei are rapidly exchanged for linker histone *B4*, and the transplanted nuclei begin to swell and initiate decondensation ([@bib3], [@bib17]); furthermore, in mouse SCNT the same phenomenon is observed with *H1foo* ([@bib2]). Unlike other somatic linker histones, *B4* and *H1foo* do not restrict the accessibility of the linker DNA, but decondense the chromatin and permit transcriptional activation ([@bib12], [@bib30]).

Based on these studies, we hypothesized that *H1foo* has a beneficial effect on iPSC generation. Here, we show that *H1foo* enhanced the generation of mouse iPSCs when co-expressed with *Oct4*, *Sox2*, and *Klf4*. Furthermore, *H1foo* promoted several in vitro differentiation characteristics with low heterogeneity in iPSCs that were similar to those of ESCs. Specifically, *H1foo* enhanced germline-competent chimeric mouse generation. These findings indicate that *H1foo* contributes to the generation of higher-quality iPSCs.

Results {#sec2}
=======

Exogenous Expression of *H1foo* Promotes Qualified iPSC Generation {#sec2.1}
------------------------------------------------------------------

We examined the effect of exogenous *H1foo* on somatic cell reprogramming by introducing *H1foo* during iPSC generation with *Oct4*, *Sox2*, and *Klf4* (OSK) or *Oct4*, *Sox2*, *Klf4*, and *c-Myc* (OSKM). Retrovirus vector-mediated exogenous *H1foo* was exclusively expressed in the nucleus of adult mouse tail-tip fibroblasts ([Figures 1](#fig1){ref-type="fig"}Aand [S1](#mmc1){ref-type="supplementary-material"}A) and highly expressed peripherally in the nucleus ([Figure 1](#fig1){ref-type="fig"}B). SCNT into oocytes induced swelling of nuclei and chromatin decondensation ([@bib9], [@bib36], [@bib40]), so we investigated the effect of *H1foo* on nuclei ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We found that *H1a*, *H1c*, and *H1foo* had no significant effect on nuclear swelling ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). However, interestingly, only *H1foo* reduced the intensively stained area, namely the heterochromatin area ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Next, we addressed whether intrinsic *H1foo* might be expressed during iPSC generation from mouse embryonic fibroblasts (MEFs) by introducing OSK or OSKM. However, we did not observe detectable intrinsic *H1foo* expression ([Figure 1](#fig1){ref-type="fig"}C). Co-expression of *H1foo* with OSK (OSKH) significantly enhanced the number of alkaline phosphatase-positive ESC-like colonies compared with OSK, OSK and *H1a* (OSKA), or OSK and *H1c* (OSKC) ([Figure 1](#fig1){ref-type="fig"}D). The OSKH-iPSCs expressed pluripotency markers similarly to control iPSCs (OSK), and *H1foo* was silenced ([Figure 1](#fig1){ref-type="fig"}E). We then examined the effect of *H1foo* on qualified iPSC generation using tail-tip fibroblasts from *Nanog*-GFP transgenic adult mice ([@bib27]) ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Interestingly, *H1foo* also maximally promoted *Nanog*-GFP-positive colony generation (8-fold) during iPSC generation by OSK ([Figure 1](#fig1){ref-type="fig"}F). Notably, *H1foo* specifically enhanced GFP-positive colonies as opposed to GFP-negative colonies ([Figure 1](#fig1){ref-type="fig"}G).

Characteristics of OSKH-iPSC Generation {#sec2.2}
---------------------------------------

Next, we examined the iPSC characteristics produced by OSK and OSKH. The OSKH-iPSCs expressed pluripotency markers similar to those of OSK-iPSCs. Meanwhile the transgenes, including *H1foo*, were silenced ([Figure 2](#fig2){ref-type="fig"}A). Regarding the growth rate of iPSCs, there was no significant difference between OSK- and OSKH-treated cells ([Figure S1](#mmc1){ref-type="supplementary-material"}F). We investigated the differences in global gene-transcriptome profiles among ESCs, three replicates of OSK-iPSCs, and four replicates of OSKH-iPSCs. All cell types were remarkably similar and showed a correlation coefficient (R^2^) of 0.99 ([Figures 2](#fig2){ref-type="fig"}B and 2C). We then examined DNA demethylation in the promoter regions of pluripotency marker genes ([Figure S1](#mmc1){ref-type="supplementary-material"}H) and the differentiation potencies by teratoma formation ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Furthermore, we focused on genes differentially expressed between OSK-iPSCs and OSKH-iPSCs. We chose eight differentially expressed genes, which were statistically significant with more than a 2-fold difference between OSK-iPSCs and OSKH-iPSCs (p \< 0.05). Many of the genes showed more similar expression patterns between OSKH-iPSCs and ESCs than between OSK-iPSCs and ESCs ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2H), but the expression levels of these transcripts were heterogeneous among the replicates in the same cell type, indicating that those genes would not have a definitive role in stem cell properties. Although a definitive marker that reflects the quality of iPSCs has not been found, aberrant epigenetic silencing of the *Dlk1-Dio3* gene cluster could indicate developmental potency, particularly because it contributes to the ratio of chimerism in mouse iPSCs ([@bib32]). We analyzed the methylation status of an intergenic differentially methylated region (*IG*-DMR) that is located between the *Dlk1* and *Gtl2* genes and a *Gtl2* differentially methylated region (*Gtl2-*DMR) ([Figures 2](#fig2){ref-type="fig"}D and 2E). Both loci in OSKH-iPSCs were highly demethylated, similarly to ESCs and MEFs. We next investigated the expression of several transcripts that increase or diminish in the early reprogramming phase ([@bib21]). Interestingly, OSKH-induced MEFs showed significant upregulation of several early reprogramming markers ([Figures S2](#mmc1){ref-type="supplementary-material"}I, S2J, and S2K) and downregulation of fibroblast markers ([Figures S2](#mmc1){ref-type="supplementary-material"}L and S2M) in comparison with OSK- or OSKA-induced MEFs. We confirmed that OSKH correctly traces the same pathway already reported.

H1foo Enhances the In Vitro Differentiation Potential {#sec2.3}
-----------------------------------------------------

Next, we asked whether *H1foo* could improve the quality of iPSCs. Often iPSCs highly express pluripotency markers but show poor differentiation efficiency in vitro, including characteristics such as a low number of embryoid bodies (EBs) and frazzled EBs with poor differentiation potential. Moreover, this undesired trend is highly apparent in low-passage iPSCs and is correlated to the remnant source cell epigenetic memories ([@bib19], [@bib28]). We examined the differentiation potency by EB formation in low-passage (P5) OSK-iPSCs, OSKH-iPSCs, and two types of ESCs as controls. First, we examined the number and the size of EBs at 5 days after differentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}A), which were more similar between OSKH-iPSCs and ESCs than between OSK-iPSCs and ESCs ([Figures 3](#fig3){ref-type="fig"}A and 3B). Furthermore, the variance of EB size was smaller in OSKH-iPSCs than in OSK-iPSCs ([Figures 3](#fig3){ref-type="fig"}C and 3D). OSKH-iPSCs expressed a higher content of proliferation markers than OSK-iPSCs ([Figures 3](#fig3){ref-type="fig"}E and 3F). However, a significant difference was not observed in the differentiation marker profiles among ESCs, OSK-iPSCs, and OSKH-iPSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We also examined the population of apoptotic cells during differentiation. Apoptosis in OSKH-iPSCs was suppressed compared with OSK-iPSCs ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}C). Taken together, the data suggest that *H1foo* causes iPSCs to be more adaptable to in vitro differentiation conditions and promotes the homogeneity of EBs.

H1foo Enhances the In Vivo Differentiation Potential {#sec2.4}
----------------------------------------------------

We finally investigated the in vivo differentiation potential of OSK-iPSCs and OSKH-iPSCs using a co-culture aggregation method ([@bib4]). First we examined the chromosome number, which showed no significant difference in chromosomal abnormality between OSK-iPSCs and OSKH-iPSCs ([Figure 4](#fig4){ref-type="fig"}A). Each iPSC clone was aggregated with 100 ICR mouse embryos at the eight-cell stage, and chimeric embryos were transferred into the uteri of pseudopregnant females. Notably, OSKH-iPSCs generated more live chimeras, with higher chimerism, than OSK-iPSCs ([Figures 4](#fig4){ref-type="fig"}B, 4C, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). Moreover, some OSKH-iPSC clones generated more 100% chimeras than ESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Germline transmission potential is one of the most stringent hallmarks of pluripotent stem cells. We examined the germline transmission from 100% chimeric mice by in vitro fertilization. OSKH-iPSCs generated many pups with colored coats, confirming the favorable germline transmission potential of OSKH-iPSCs ([Figures 4](#fig4){ref-type="fig"}E, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). We did not find any phenotypic abnormalities in these pups.

Discussion {#sec3}
==========

*H1foo* promoted the generation of *Nanog*-GFP-positive colonies when it was co-expressed with OSK. Notably, the proportion of GFP-positive colonies was improved to 90%. OSKH-iPSCs demonstrated differentiation potency more similar to that of ESCs than did OSK-iPSCs, especially with respect to in vitro EB formation, chimerism, and germline transmission in vivo. We also examined the effect of *H1foo* with *Oct4*, *Sox2*, *Klf4*, and *c-Myc*, but the number of alkaline phosphatase-positive colonies and *Nanog*-GFP colonies, and the proportion of GFP-positive colonies were not significantly different to those of OSKM-iPSCs. *c-Myc* promotes iPSC generation but is not essential for reprogramming. On the other hand, *c-Myc* lowers the proportion of *Nanog*-GFP-positive colonies and increases the tumorigenicity of cells ([@bib24]). Therefore, it is preferable to omit *c-Myc* in iPSC generation, although it is still commonly used to promote reprogramming efficiency. We showed here that *H1foo* could be substituted for *c-Myc* in terms of reprogramming efficiency and showed superiority with respect to qualifying iPSCs.

Recent studies have demonstrated that oocyte constituents play a key role in somatic cell reprogramming in SCNT. Co-expression of maternal-specific factors in oocytes, such as Glis1 ([@bib22]) and TH2A/TH2B ([@bib31]), enhances the reprogramming efficiency of iPSC generation. Investigation of maternal-specific factors in oocytes has great potential for innovating somatic cell reprogramming and deciphering the reprogramming mechanisms ([@bib10]). *H1foo* is specifically expressed during the germinal vesicle stage and is essential for oocyte maturation ([@bib7], [@bib9]). Interestingly, exogenous expression of *H1foo* in ESCs leads to the prevention of differentiation in vitro due to continuous pluripotency gene activation ([@bib12]). In our study, *H1foo* was properly silenced in generated iPSCs, which induced successful reprogramming but did not hinder the differentiation potency of OSKH-iPSCs.

The detailed molecular mechanisms regarding how *H1foo* enhances the reprogramming efficiency in iPSC generation and why OSKH-iPSCs exhibit improved quality remain elusive. The higher-order chromatin structure is crucially dependent on architectural chromatin proteins, including the family of linker histone proteins. Although somatic cells contain numerous linker histone variants, only one, *H1foo*, is present in mouse oocytes ([@bib37]). In the mouse egg, somatic linker histones in sperm-derived chromatin are rapidly replaced by H1foo after fertilization ([@bib37]). In SCNT oocytes, the somatic linker histone H1c in the donor chromatin is also rapidly replaced by H1foo in mice ([@bib9], [@bib40]). In *Xenopus* SCNT, oocyte-specific linker histone B4 loading to genome-wide somatic chromatin is required for successful reprogramming ([@bib17], [@bib18], [@bib23]). In the early phase of the reprogramming process, global loss of histone H3 lysine 27 trimethylation (H3K27me3) occurs and epigenetic modification affects the status of heterochromatin ([@bib16]). In our study, *H1foo* reduced the heterochromatin area, which is consistent with previous reports that *H1foo* keeps chromatin looser than somatic H1 and other linker histones, and may support the generation of a more suitable chromatin state for reprogramming. These data suggest that dominant occupancy of oocyte-specific linker histone in donor chromatin may be required for successful reprogramming and might erase the parental epigenetic status. To determine whether innate *H1foo* would cooperatively induce reprogramming during iPSC generation by OSK, we examined *H1foo* expression during iPSC generation by OSK. We did not detect *H1foo* expression, which suggests that *H1foo* is not essential for OSK-dependent reprogramming. Therefore, we did not perform loss-of-function experiments such as *H1foo* knockdown by small interfering RNA.

*H1foo* induced successful reprogramming for iPSC generation in a stringent assay, thus contributing to chimerism and germline transmission. Although in vivo experiments cannot be performed in humans, it is important to generate high-quality iPSCs without variation among different iPSC lines.

Experimental Procedures {#sec4}
=======================

Details of all procedures are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

All experiments were performed in accordance with the Keio University Animal Care Guidelines and were approved by the Ethics Committee of Keio University (20-041-4), which conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
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![Exogenous Expression of *H1foo* Promotes iPSC Generation\
(A) Immunostaining for H1foo (red), including nuclei stained with DAPI (blue) and bright-field (BF) images. Scale bar, 50 μm.\
(B) Immunostaining for H1foo (red) with a 2D image (left) and a 2.5D image (right). The density of H1foo is depicted by the height in the 2.5D view. Scale bar, 5 μm.\
(C) qRT-PCR analysis of endogenous *H1foo* expression during reprogramming, normalized by *H1foo* expression in *H1foo*-overexpressed MEFs (n = 3 independent experiments).\
(D) Alkaline phosphatase-positive iPSC colony formations for OSK, OSK with *H1a* (OSK + *H1a*; OSKA), OSK with *H1c* (OSK + *H1c*; OSKC), and OSK with *H1foo* (OSK + *H1foo*; OSKH). Error bars represent the SEM (n = 3 independent experiments). ^∗^p \< 0.05.\
(E) Immunostaining for pluripotency markers (OCT4 \[green\], SSEA1 \[green\], and Nanog \[red\]), including *H1foo* (red) and nuclei stained with DAPI (blue) in OSK-iPSCs and OSKH-iPSCs. Scale bars, 20 μm.\
(F) Number of *Nanog-*GFP-positive iPSC colonies in each experiment (n = 5 independent experiments).\
(G) Proportion of *Nanog-*GFP-positive colonies to the total number of ESC-like colonies. Error bars represent the SEM (n = 5 independent experiments). ^∗^p \< 0.05.](gr1){#fig1}

![Characteristics of OSKH-Induced iPSCs\
(A) qRT-PCR analysis of pluripotency genes and *H1foo* in iPSCs. Error bars represent the SEM (n = 3 independent experiments).\
(B and C) Pairwise scatterplots of global gene-expression cDNA microarray patterns of OSKH-iPSCs (n = 4) compared with ESC (n = 1) (B) or OSK-iPSCs (n = 3) (C). The gray lines indicate log~2~ 2-fold changes in gene-expression levels between the paired cell types.\
(D and E) Degree of DNA methylation at IG-DMR and Gtl2-DMR in four OSK iPSC clones, four OSKH-iPSC clones, and ESCs, as well as MEFs analyzed by pyrosequencing. Error bars represent the SEM (n = 3 independent experiments).](gr2){#fig2}

![In Vitro Differentiation Potential in OSKH-iPSCs\
(A) Number of EBs on day 5 after differentiation. Error bars represent the SEM (n = 3 independent experiments). ^∗^p \< 0.05.\
(B) Size of EBs on day 5 after differentiation. Error bars represent the SEM (n = 3 independent experiments). ^∗^p \< 0.05.\
(C) Variance of EB sizes from each ESCs and iPSCs (n = 3 independent experiments).\
(D) Variation of EB sizes. Each bar represents one experiment.\
(E and F) Cell-proliferation markers Ki67 (E) and proliferating cell nuclear antigen (PCNA; F) on day 2 after differentiation. Error bars represent the SEM (n = 3 independent experiments). ^∗^p \< 0.05.\
(G) Apoptotic cell distribution determined by fluorescence-activated cell sorting analysis of cells labeled with annexin V-fluorescein isothiocyanate and propidium iodide (PI) on day 1 after differentiation induction. Error bars represent the SEM (n = 3 independent experiments). ^∗^p \< 0.05.](gr3){#fig3}

![In Vivo Differentiation Potential in OSKH-iPSCs\
(A) Chromosome number of each iPSC.\
(B) Chimeric mice generated from OSK-iPSCs or OSKH-iPSCs.\
(C) Number of agouti coat colored chimeric mice derived from each of four replicates of iPSCs.\
(D) Birth rate of 100% chimeric mice (100% chimeric mice/embryos transferred).\
(E) The coat color of pups from a 100% chimeric OSKH mouse shows germline transmission.](gr4){#fig4}
